Everything below concerns Preclinical study. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-11. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
== Weblinks == „Deutschland ist kein Vitaminmangel-Land“ – Artikel der Deutschen Gesellschaft für Ernährung (Memento vom 11. September 2012 im Internet Archive) Ernährungsbericht der Deutschen Gesellschaft für Ernährung 2004 (Memento vom 11. September 2012 im Internet Archive)
Ein ACE-Getränk ist ein alkoholfreies Erfrischungsgetränk aus Frucht- und Gemüsesäften, das mit Vitamin A, Vitamin C und Vitamin E angereichert ist. Meist sind ACE-Getränke aus Orangensaft, Karottensaft, Wasser, Zucker sowie Beta-Carotin (als Provitamin A) und den Vitaminen C und E zusammengesetzt. Sie gehören zu den funktionellen Getränken, die nach Angaben der Hersteller wegen ihrer Zusätze nicht nur den Durst löschen, sondern auch eine gesundheitsfördernde Funktion erfüllen sollen. Viele der angebotenen Getränke enthalten relativ viel Zucker. Die Deutsche Gesellschaft für Ernährung und die Verbraucherzentralen bezweifeln grundsätzlich deren gesundheitlichen Nutzen beziehungsweise sehen die Versorgung der Bevölkerung mit Vitaminen als ausreichend.
== Vermarktung und Verbreitung == Üblicherweise wird Actimel in 100-ml-Flaschen verkauft, meist in sogenannten „Vorteilspackungen“, die 8, 6 oder 4 Fläschchen beinhalten. Daneben werden auch einige 12- oder 16-Stückpackungen verkauft. Der Hersteller behauptet, Actimel stärke die natürlichen Abwehrkräfte des Körpers durch den Einsatz der patentierten Bakterienkultur Lactobacillus casei DN-114001 (vermarktet als Lactobacillus casei Defensis oder Immunitas). Actimel enthält allerdings auch die traditionellen Joghurtkulturen Lactobacillus delbrueckii subsp. bulgaricus und Streptococcus salivarius subsp. thermophilus. Im Jahr 2006 wurde mit Actimel ein Umsatz von mehr als 1,4 Milliarden Euro im Einzelhandel erzielt. Das Getränk wird in mehr als 20 europäischen Ländern sowie in Südamerika und dem Nahen Osten vertrieben. Actimel wurde als DanActive in den Vereinigten Staaten auf regionaler Basis im Jahr 2004 (Geschmacksrichtungen Erdbeer, Vanille und Heidelbeere) verkauft, bis es im Jahr 2007 eine landesweite Markteinführung mit weiteren Geschmacksrichtungen gab. In Deutschland ist Actimel mit 70 Prozent Marktführer bei probiotischen Joghurtgetränken und laut Danone Wachstumstreiber für den Gesamtumsatz von 470 Millionen Euro. Laut des Marktforschungsinstituts Nielsen hat der Konzern von Januar bis Oktober 2008 50 Millionen Euro allein für Werbemaßnahmen in Deutschland investiert. Werbegesicht von Actimel in Deutschland ist Guido Maria Kretschmer.
Joghurt entrahmte Milch Zucker oder Flüssigzucker Traubenzucker L. Casei Immunitas Den Herstellerangaben zufolge haben die Actimel-Produkte die folgenden Nährwerte (die Angaben gelten jeweils pro Becher für die „Classic“-Version der Produkte; die Produkte mit Frucht- oder Vanillegeschmack haben meist leicht abweichende Nährwerte, zum Beispiel einen erhöhten Brennwert):
Sources: de.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.